Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3
+
Regulatory T Cells (Tregs) in Human Cancers-Letter
Clin Cancer Res
.
2019 Jun 1;25(11):3468.
doi: 10.1158/1078-0432.CCR-18-3740.
Epub 2018 Dec 4.
Authors
Roberto Ferrara
1
2
,
Sandrine Susini
3
,
Aurelien Marabelle
4
5
Affiliations
1
Medical Oncology, Istituto Nazionale dei Tumori, Milan, Italy.
2
Laboratory for Immunomonitoring in Oncology (L.I.O.), Gustave Roussy, France.
3
INSERM U1015, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
4
INSERM U1015, Gustave Roussy, Université Paris-Saclay, Villejuif, France. aurelien.marabelle@gustaveroussy.fr.
5
Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
PMID:
30514779
DOI:
10.1158/1078-0432.CCR-18-3740
No abstract available
Publication types
Letter
Comment
MeSH terms
CTLA-4 Antigen
Forkhead Transcription Factors
Humans
Immunotherapy
Neoplasms*
T-Lymphocytes, Regulatory*
Substances
CTLA-4 Antigen
FOXP3 protein, human
Forkhead Transcription Factors